Trials / Completed
CompletedNCT02082119
Hypofractionated IMRT With Temozolomide for HGG
Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed HGGs after surgery. Primary endpoint: progression free survival (PFS), Overall Survival (OS) and Toxicity. Secondary endpoint: to evaluate Quality of life (QoL) of patients after surgery, concomitant chemoradiotherapy and adjuvant chemotherapy through neuropsychological examination.
Detailed description
We designed a study of a hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc approach. The potential advantage of this approach is to deliver a more selective irradiation to tumor's target with reducing dose to normal brain and to allow to deliver a higher dose, optimizing the therapeutic window
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Hypofractionated IMRT | Hypofractionated IMRT |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2014-03-10
- Last updated
- 2020-10-12
- Results posted
- 2020-10-12
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02082119. Inclusion in this directory is not an endorsement.